The Client |
|
Established in 1993, this Singapore-based precision engineering firm has spent over three decades building a reputation for high-quality customised equipment and fixture solutions. Operating from an 800 sqm production facility equipped with CNC machining, milling, grinding, and EDM wire-cutting capabilities, the company serves clients across medical technology, aerospace, electronics, and industrial automation. With ISO 9001:2015 and bizSAFE3 certifications, and a team of 28 employees, the company has built long-standing relationships with organisations such as ST Engineering, Leica Instruments, and the National University of Singapore, while extending its market reach through authorised distributors in China and the Netherlands.
The company identified a strategic pivot point: the growing global demand for precision cell culture systems in clinical and biotechnology settings. Recognising that conventional manual bioreactors were increasingly inadequate for the sterility, reproducibility, and scalability requirements of regenerative medicine and personalised therapies, the company set out to develop its own proprietary Automated Bioreactor. The system would fully automate critical bioprocessing steps including cell seeding, medium exchange, contamination monitoring, and cell isolation, while meeting Good Manufacturing Practice (GMP) standards and positioning the firm to commercialise a proprietary product in the high-growth life sciences market.
Translating decades of precision engineering expertise into a first-of-kind bioprocessing platform required more than technical capability. The company needed a partner who could package this ambition into a structured, government-ready funding proposal, and who understood how to navigate Enterprise Singapore's evaluation criteria for innovation and productivity projects.
The company identified a strategic pivot point: the growing global demand for precision cell culture systems in clinical and biotechnology settings. Recognising that conventional manual bioreactors were increasingly inadequate for the sterility, reproducibility, and scalability requirements of regenerative medicine and personalised therapies, the company set out to develop its own proprietary Automated Bioreactor. The system would fully automate critical bioprocessing steps including cell seeding, medium exchange, contamination monitoring, and cell isolation, while meeting Good Manufacturing Practice (GMP) standards and positioning the firm to commercialise a proprietary product in the high-growth life sciences market.
Translating decades of precision engineering expertise into a first-of-kind bioprocessing platform required more than technical capability. The company needed a partner who could package this ambition into a structured, government-ready funding proposal, and who understood how to navigate Enterprise Singapore's evaluation criteria for innovation and productivity projects.
How RIC Helped |
|
Grant Secured:
RIC secured approval under the Enterprise Development Grant (EDG), Innovation and Productivity track, administered by Enterprise Singapore. The approved grant quantum is S$235K covering 50% of qualifying costs across manpower, third-party development and fabrication, materials, training, consultancy, and audit fees.
Scope of RIC’s Consulting and Advisory Services:
RIC provided end-to-end advisory support from proposal design through to approved offer, covering the following:
RIC secured approval under the Enterprise Development Grant (EDG), Innovation and Productivity track, administered by Enterprise Singapore. The approved grant quantum is S$235K covering 50% of qualifying costs across manpower, third-party development and fabrication, materials, training, consultancy, and audit fees.
Scope of RIC’s Consulting and Advisory Services:
RIC provided end-to-end advisory support from proposal design through to approved offer, covering the following:
- R&D Programme Design: RIC worked with the client's engineering and laboratory teams to define the six core development pillars of the automated bioreactor: an automated cell seeding system, a real-time monitoring sensor array, an automated medium change function, an automated cell and medium isolation system, a sterile enclosure structure meeting GMP requirements, and a cell culture monitoring integration framework with a pathway toward future AI-assisted optimisation. Each pillar was framed around a clear productivity and innovation rationale, directly addressing limitations of legacy manual systems.
- Milestone and KPI Structuring: RIC structured the project deliverables around a 12-month development cycle, with a completion criterion tied to successful mechanical and software functional testing, as well as live cell culture validation. Milestones were mapped to the qualifying period and aligned with the agency's Annex 3 deliverables framework, ensuring the client had a clear and auditable path to final claim submission.
- Financial Cost Modelling: RIC built the qualifying cost model across six expenditure categories: internal manpower salaries (covering Software Programmers), third-party materials and consumables, hardware procurement, system development and fabrication works, training, and regulatory consultancy, all via a credible system integrator. A separate SOLIDWORKS software licence through SEACAD Technologies was included as a qualifying software cost. The model maximised qualifying expenditure while remaining fully defensible under Enterprise Singapore's audit requirements.
- Stakeholder Management and Submission: RIC managed the full submission process through the Business Grants Portal, coordinating the application timeline from initial lodgement to offer issuance. This included supporting to client in handling the engagement with Enterprise Singapore's Healthcare and Biomedical team and ensuring all supporting documentation, vendor justifications, and project narratives were complete and aligned with the agency's assessment criteria.
Outcomes |
|
On the workforce front, the approved project directly funds the hiring of a Software Programmer/Leader to lead the system's software integration and control architecture. Looking ahead, the company has committed to creating three additional roles over the post-project commercialisation phase: a Sales and Business Development Manager to drive clinical and institutional sales, a Regulatory Affairs Specialist to navigate medical device certification requirements across markets such as the US and EU, and an R&D Engineer with biomedical or mechanical engineering expertise to support continuous product improvement. Total headcount is projected to grow from 28 to 32 over the three years following project completion.
The technology deliverables are specific and measurable. Upon completion, the bioreactor will feature a fully integrated automated cell seeding system, continuous sensor-based monitoring of cell shape, confluency, culture conditions, and contamination risk, an automated medium exchange function to maintain sterile and nutrient-consistent culture conditions, and an automated isolation system for cells, extracellular vesicles, and other target materials. The system will be built to GMP standards, eliminating the need for a separate GMP-certified lab space, and will be designed for future AI integration to enable predictive process optimisation.
The collaboration with a Research Scientist from NUS, confirmed through a formal support letter, adds scientific validation to the project. This IHL partnership provides the client with access to cell culture expertise for biological optimisation, testing, and certification of the system's performance across multiple cell types and clinical applications.
From a commercial standpoint, the EDG grant meaningfully reduces the client's capital burden on a total project cost of approximately S$1.09 million. With a target unit price of S$200,000 per machine and projected recurring consumables revenue of S$144,000 per machine per year, the path to revenue is clearly modelled and grounded in a specific clinical use case: personalised cell therapies requiring up to four patient treatments per machine per month.
This engagement demonstrates RIC's ability to bridge the gap between an engineering company's innovation ambitions and the structured language of government grant evaluation. The combination of rigorous cost modelling, precise milestone structuring, and a compelling technology narrative enabled the client to secure meaningful public funding for a product that is genuinely novel in the Singapore precision engineering landscape.
The technology deliverables are specific and measurable. Upon completion, the bioreactor will feature a fully integrated automated cell seeding system, continuous sensor-based monitoring of cell shape, confluency, culture conditions, and contamination risk, an automated medium exchange function to maintain sterile and nutrient-consistent culture conditions, and an automated isolation system for cells, extracellular vesicles, and other target materials. The system will be built to GMP standards, eliminating the need for a separate GMP-certified lab space, and will be designed for future AI integration to enable predictive process optimisation.
The collaboration with a Research Scientist from NUS, confirmed through a formal support letter, adds scientific validation to the project. This IHL partnership provides the client with access to cell culture expertise for biological optimisation, testing, and certification of the system's performance across multiple cell types and clinical applications.
From a commercial standpoint, the EDG grant meaningfully reduces the client's capital burden on a total project cost of approximately S$1.09 million. With a target unit price of S$200,000 per machine and projected recurring consumables revenue of S$144,000 per machine per year, the path to revenue is clearly modelled and grounded in a specific clinical use case: personalised cell therapies requiring up to four patient treatments per machine per month.
This engagement demonstrates RIC's ability to bridge the gap between an engineering company's innovation ambitions and the structured language of government grant evaluation. The combination of rigorous cost modelling, precise milestone structuring, and a compelling technology narrative enabled the client to secure meaningful public funding for a product that is genuinely novel in the Singapore precision engineering landscape.